Fellowships awarded in 2017-18
Adriana Forero -T32 Cardio vascular pathology TG Solomon and Julian Smith -T32 Immunology TG Matthew Hendricks -T32 Pathobiology TG Frank Soveg - T32 CMB TG Frank received F31 Ruth L. Kirschstein National Research Service Award. This competitive and prestigious NIH predoctoral fellowship will support his dissertation research. The title of his project is “Defining the roles of OAS1 isoforms in RNA virus immunity.” Frank is interested in how the cell-intrinsic innate response to viruses achieves specificity. One way he believes this is happening is through isoform diversification of antiviral genes such as oligo adenylate synthetase 1 (OAS1). By producing isoforms with different antiviral specificities, the immune system can recognize and respond to different viral threats.Pharmacy students from Mukogawa Women's University, Hyōgo, Japan visited Ram Lab on August 24th 2017. They spent the afternoon listening to the research conducted in the Ram lab as well as learning molecular biology techniques.
Johannes Schwerk and Adriana Forero win travel grants to present at Cytokines 2017 in Kanazawa Japan.
Frank Soveg wins a poster award at UW Immunology retreat !! Dr. Forero is awarded the CVP training grant to study the role of myomiRs in controlling interferon signaling and inflammation in the heart. For more information see http://courses.washington.edu/cvptg/ The virus that causes hepatitis C protects itself by blocking signals that drive elements of liver cells’ immune defenses, University of Washington researchers report in a new study. “The finding helps explain why many patients fail certain drug treatments, and should help develop more effective alternate treatment protocols,” said Ram Savan, a UW assistant professor of immunology and the study's corresponding author. Hepatitis C virus is the most common cause of chronic hepatitis and the leading U.S. cause of liver cancer. It is primarily spread through contact with infected blood. Each year, more than 30,000 Americans become infected and as many as 85 percent develop life-long chronic infections. Of these patients, about one in 10 will eventually develop cirrhosis and liver cancer.
|